









Markets
/
Stocks
/
nasdaq-rckt
/

Rocket Pharmaceuticals Inc

RCKT

4.680USD

+0.410+9.60%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

18.58MMarket Cap

LossP/E TTM



Rocket Pharmaceuticals Inc

4.680

+0.410+9.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rocket Pharmaceuticals Inc

Currency: USD Updated: 2026-03-25

Key Insights

Rocket Pharmaceuticals Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 127 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rocket Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

127 / 391

Overall Ranking

247 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Rocket Pharmaceuticals Inc Highlights

StrengthsRisks

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Overvalued

The company’s latest PE is -2.33, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 99.47M shares, decreasing 20.03% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 13.49K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.90.

Analyst Rating

Based on 14 analysts

Hold

Current Rating

8.205

Target Price

+89.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Rocket Pharmaceuticals Inc is 5.45, ranking 364 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rocket Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Rocket Pharmaceuticals Inc is 7.73, ranking 84 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.33, which is -61.89% below the recent high of -0.89 and -351.13% above the recent low of -10.52.

Score

Industry at a Glance

Previous score

7.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 127/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Rocket Pharmaceuticals Inc is 6.86, ranking 322 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 16.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Hold

Current Rating

8.205

Target Price

+89.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Rocket Pharmaceuticals Inc

RCKT

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Rocket Pharmaceuticals Inc is 6.77, ranking 186 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.39 and the support level at 4.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.22

Change

0.55

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.170

Neutral

RSI(14)

55.738

Neutral

STOCH(KDJ)(9,3,3)

36.795

Buy

ATR(14)

0.390

Low Volatility

CCI(14)

-13.092

Neutral

Williams %R

57.037

Sell

TRIX(12,20)

0.540

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.364

Buy

MA10

4.544

Buy

MA20

4.700

Sell

MA50

4.026

Buy

MA100

3.690

Buy

MA200

3.448

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Rocket Pharmaceuticals Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 91.91%, representing a quarter-over-quarter increase of 2.37%. The largest institutional shareholder is The Vanguard, holding a total of 8.54M shares, representing 7.87% of shares outstanding, with 28.40% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

17.69M

The Vanguard Group, Inc.

Star Investors

6.89M

+12.97%

BlackRock Institutional Trust Company, N.A.

6.02M

-5.16%

Two Sigma Investments, LP

3.41M

+5.48%

Suvretta Capital Management, LLC

3.84M

-7.24%

Monaco asset management S.A.M.

2.89M

+538.80%

Morgan Stanley & Co. LLC

2.66M

+31.69%

Newtyn Management, LLC

2.50M

+25.14%

D. E. Shaw & Co., L.P.

2.19M

+120.56%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rocket Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.37. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.